Last reviewed · How we verify

NCT06008639

Efficacy and Safety of Near Infrared Light Therapy for Alzheimer's Disease

Status unknown NA Last updated 6 September 2023
What this trial tests

NA trial testing treatment group-Device: NirsCure - Active NirsCure - Active settings in Mild to Moderate Alzheimer's Disease in 80 participants. Status unknown.

Timeline
1 March 2023
Primary endpoint
31 December 2024
31 December 2024

Quick facts

Lead sponsorDanyang Huichuang Medical Equipment Co., Ltd.
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment80
Start date1 March 2023
Primary completion31 December 2024
Estimated completion31 December 2024
Sites2 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Danyang Huichuang Medical Equipment Co., Ltd.

Who can join

50 and older, any sex, with Mild to Moderate Alzheimer's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To explore the efficacy and safety of near infrared light therapy for Alzheimer's disease. Each subject will be numbered and their medical records will be established. The subjects will be randomly assigned to the treatment group or the control group for 30 minutes/day (5-6 days a week) for 4 months while the treatment group is active settings and the control group is sham settings.Follow-up visits will be conducted at 2 months, 4 months and 2 months after treatment. At each follow-up, scale assessment, blood, MRI, and EEG were observed

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Danyang Huichuang Medical Equipment Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06008639.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing